Literature DB >> 24135577

Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine.

Xuelian Wang1, Hannah N Coleman, Uma Nagarajan, Horace J Spencer, Mayumi Nakagawa.   

Abstract

A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of a Candida skin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus therapeutic vaccine. The goal of this current study was to investigate the mechanisms of how Candida enhances the vaccine immune responses. Maturation effects on Langerhans cells, capacity to proliferate T-cells, expression of cytokines and pattern recognition receptors by Langerhans cells, and ability to induce Th1, Th2, and Th17 responses were investigated in healthy subjects. The vaccine, human papillomavirus peptides with Candida, demonstrated partial maturation effects on Langerhans cells indicated by significantly up-regulated CD40 (p=0.00007) and CD80 (p<0.00001) levels, and showed T-cell proliferative capacity (p<0.00001) when presented by Langerhans cells in vitro. Interestingly, the maturation effects were due to the peptides while Candida was responsible for the T-cell proliferation. The cytokine profile (IL-1β, IL-6, IL-8, IL-10, IL-12p40, IL-23Ap19, IFN-γ and TNF-α) of Langerhans cells treated with the vaccine or Candida alone showed that IL-12p40 mRNA was most frequently induced, and IL-12p70 protein was detected in the supernatants. The presence of pattern recognition receptors known to associate with Candida albicans (DC-SIGN, dectin-1, dectin-2, galectin-3, mincle, mannose receptor, Toll-like receptors-1, 2, 4, 6 and 9) were demonstrated in all subjects. On the other hand, the induction of Th1 response demonstrated by IFN-γ secretion by CD4 cells stimulated with the vaccine or Candida pulsed Langerhans cells was demonstrated only in one subject. In summary, the Langerhans cell maturation effects of the vaccine were due to the peptides while the T-cell proliferative capacity was derived from Candida, and the most frequently induced cytokine was IL-12.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APCs; Adjuvant; Candida; HPV; Human papillomavirus; LCs; Langerhans cells; MFI; PAMPs; PBMC; PE; PRRs; antigen presenting cells; human papillomavirus; mean fluorescence intensity; pathogen-associated molecular patterns; pattern recognition receptors.; peripheral blood mononuclear cells; phycoerythrin; qRT-PCR; quantitative real-time PCR

Mesh:

Substances:

Year:  2013        PMID: 24135577      PMCID: PMC3856859          DOI: 10.1016/j.vaccine.2013.10.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  Treatment of warts with Candida antigen injection.

Authors:  R C Phillips; T S Ruhl; J L Pfenninger; M R Garber
Journal:  Arch Dermatol       Date:  2000-10

Review 2.  Cutaneous dendritic cells.

Authors:  Jenny Valladeau; Sem Saeland
Journal:  Semin Immunol       Date:  2005-08       Impact factor: 11.130

Review 3.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

4.  Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86.

Authors:  A N Schweitzer; F Borriello; R C Wong; A K Abbas; A H Sharpe
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

5.  Effects of caspofungin, Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs.

Authors:  Stefanie Salvenmoser; Marc J Seidler; Alexander Dalpke; Frank-Michael C Müller
Journal:  FEMS Immunol Med Microbiol       Date:  2010-10

6.  Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens.

Authors:  M Nakagawa; D P Stites; S Patel; S Farhat; M Scott; N K Hills; J M Palefsky; A B Moscicki
Journal:  J Infect Dis       Date:  2000-07-28       Impact factor: 5.226

Review 7.  Innate and adaptive immunity in Candida albicans infections and saprophytism.

Authors:  L Romani
Journal:  J Leukoc Biol       Date:  2000-08       Impact factor: 4.962

Review 8.  Antigen presentation by Langerhans cells.

Authors:  Botond Z Igyártó; Daniel H Kaplan
Journal:  Curr Opin Immunol       Date:  2012-12-12       Impact factor: 7.486

9.  The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans.

Authors:  Christine A Wells; Judith A Salvage-Jones; Xin Li; Kelly Hitchens; Suzanne Butcher; Rachael Z Murray; Anthony G Beckhouse; Yu-Lan-Sandra Lo; Silvia Manzanero; Christian Cobbold; Kate Schroder; Bo Ma; Sally Orr; Lauren Stewart; Daniel Lebus; Peter Sobieszczuk; David A Hume; Jennifer Stow; Helen Blanchard; Robert B Ashman
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

10.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

Authors:  Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

View more
  12 in total

Review 1.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

2.  Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination.

Authors:  Hannah N Coleman; William W Greenfield; Shawna L Stratton; Rita Vaughn; Alexander Kieber; Andrea M Moerman-Herzog; Horace J Spencer; Wilbur C Hitt; Charles Matthew Quick; Laura F Hutchins; Samuel G Mackintosh; Ricky D Edmondson; Stephen W Erickson; Mayumi Nakagawa
Journal:  Cancer Immunol Immunother       Date:  2016-03-15       Impact factor: 6.968

3.  A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine.

Authors:  Shawna L Stratton; Horace J Spencer; William W Greenfield; Gordon Low; Wilbur C Hitt; Charles M Quick; Susanne K Jeffus; Victoria Blackmon; Mayumi Nakagawa
Journal:  Clin Trials       Date:  2015-01-09       Impact factor: 2.486

4.  A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.

Authors:  William W Greenfield; Shawna L Stratton; Rebecca S Myrick; Rita Vaughn; Lisa M Donnalley; Hannah N Coleman; Maria Mercado; Andrea M Moerman-Herzog; Horace J Spencer; Nancy R Andrews-Collins; Wilbur C Hitt; Gordon M Low; Nirvana A Manning; Samantha S McKelvey; Dora Smith; Michael V Smith; Amy M Phillips; C Matthew Quick; Susanne K Jeffus; Laura F Hutchins; Mayumi Nakagawa
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

5.  Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice.

Authors:  Xingxuan Wang; Yuxin Che; Bingnan Chen; Yao Zhang; Mayumi Nakagawa; Xuelian Wang
Journal:  Int Immunopharmacol       Date:  2018-02-03       Impact factor: 4.932

6.  Uveitis Following Treatment of Verruca Vulgaris with Intralesional Candida Antigen.

Authors:  Nicholas J Crowley; John C Hagan; Jonathan A Dyer; Tyler F Brundige
Journal:  Mo Med       Date:  2017 Sep-Oct

7.  Psoriasis Exacerbation after Candida Antigen Immunotherapy Injection.

Authors:  Sameh Magdy Sarsik; Sarah Hamdy Soliman
Journal:  Skin Appendage Disord       Date:  2021-01-21

8.  A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant.

Authors:  Al-Ola Abdallah; Hannah Coleman; Mohamed Kamel; Rodney Davis; Teri Landrum; Horace Spencer; Sam Mackintosh; Fade A Mahmoud; Natasa Milojkovic; Chester Wicker; Konstantinos Arnaoutakis; Mayumi Nakagawa
Journal:  SAGE Open Med       Date:  2018-09-17

Review 9.  A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia.

Authors:  Yuejuan Liang; Mengjie Chen; Lu Qin; Bing Wan; He Wang
Journal:  Infect Agent Cancer       Date:  2019-10-26       Impact factor: 2.965

10.  Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion.

Authors:  Rahul Ravilla; Hannah N Coleman; Cheryl-Emiliane Chow; Luisa Chan; Barbara J Fuhrman; William W Greenfield; Michael Scott Robeson; Kathryn Iverson; Horace Spencer; Mayumi Nakagawa
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.